Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MGMT | P16455 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31395761 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL13554631 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL16437097 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL13498593 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL16899909 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL14763470 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL17836995 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL18576097 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL13449860 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL31577560 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4412659-A1 | IMIDAZO[4,5-C]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS | Sanofi (FR) | 2024-08-14 | — | — | EP | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023057564-A1 | IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS | SANOFI (FR) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20170137389-A1 | LINKER MOLECULE FOR MULTIPLEX RECOGNITION BY ATOMIC FORCE MICROSCOPY (AFM) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-18 | — | — | US | disclosed |
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137389-A1 | LINKER MOLECULE FOR MULTIPLEX RECOGNITION BY ATOMIC FORCE MICROSCOPY (AFM) | EPCAM, ILK, DYNLL2 | MEN1 2397/4885KMT2A 3937/4885TSHR 4542/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MEN1 2314/4885KMT2A 4146/4885TSHR 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.